Improved asparaginase administration, production and use thereof

BEVs encapsulating L-asparaginase address the instability and adverse effects of traditional treatments by providing a safer and more effective delivery system for leukemia therapies.

WO2026057996A1 Publication Date: 2026-03-19QUADRAM INSITUTE BIOSCI
1 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2025/052007
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-09-11
Filing Date
2025-09-11
Publication Date
2026-03-19

AI Technical Summary

Technical Problem

Current treatments for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) using soluble L-asparaginase require frequent high-dose regimens, leading to adverse effects such as hypersensitivity, pancreatitis, liver toxicity, and thrombosis due to the enzyme's short half-life and instability.

Method used

Utilizing bacterial extracellular vesicles (BEVs) generated by human commensal gut bacteria to naturally encapsulate L-asparaginase, providing a safer and more effective delivery system by reducing side effects and enhancing therapeutic efficacy.

Benefits of technology

BEV-encapsulated asparaginase demonstrates promising cytotoxic effects on leukemia cell lines, reducing the frequency and severity of side effects associated with traditional therapies, offering a safer and more effective treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A pharmaceutical preparation including asparaginase characterised in that the asparaginase is encapsulated or contained within bacterial extracellular vesicles (BEVs).
Need to check novelty before this filing date? Find Prior Art